175 related articles for article (PubMed ID: 16625821)
1. New targets in and potential treatments for cholesterol gallstone disease.
Doggrell SA
Curr Opin Investig Drugs; 2006 Apr; 7(4):344-8. PubMed ID: 16625821
[TBL] [Abstract][Full Text] [Related]
2. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model.
Moschetta A; Bookout AL; Mangelsdorf DJ
Nat Med; 2004 Dec; 10(12):1352-8. PubMed ID: 15558057
[TBL] [Abstract][Full Text] [Related]
3. The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes.
Landrier JF; Eloranta JJ; Vavricka SR; Kullak-Ublick GA
Am J Physiol Gastrointest Liver Physiol; 2006 Mar; 290(3):G476-85. PubMed ID: 16269519
[TBL] [Abstract][Full Text] [Related]
4. The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis.
Cariou B
Diabetes Metab; 2008 Dec; 34(6 Pt 2):685-91. PubMed ID: 19195631
[TBL] [Abstract][Full Text] [Related]
5. Differences between hepatic and biliary lipid metabolism and secretion in genetically gallstone-susceptible and gallstone-resistant mice.
Xu G; Zhao L; Fuchs M
Chin Med J (Engl); 2002 Sep; 115(9):1292-5. PubMed ID: 12411097
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of ATP8B1 expression leads to specific downregulation of the bile acid sensor FXR in HepG2 cells: effect of the FXR agonist GW4064.
Martínez-Fernández P; Hierro L; Jara P; Alvarez L
Am J Physiol Gastrointest Liver Physiol; 2009 May; 296(5):G1119-29. PubMed ID: 19228886
[TBL] [Abstract][Full Text] [Related]
7. Dissolution of cholesterol gallstones in mice by the oral administration of a fatty acid bile acid conjugate.
Gilat T; Leikin-Frenkel A; Goldiner I; Halpern Z; Konikoff FM
Hepatology; 2002 Mar; 35(3):597-600. PubMed ID: 11870372
[TBL] [Abstract][Full Text] [Related]
8. Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries.
Nicolaou KC; Evans RM; Roecker AJ; Hughes R; Downes M; Pfefferkorn JA
Org Biomol Chem; 2003 Mar; 1(6):908-20. PubMed ID: 12929628
[TBL] [Abstract][Full Text] [Related]
9. Ezetimibe prevents cholesterol gallstone formation in mice.
Zúñiga S; Molina H; Azocar L; Amigo L; Nervi F; Pimentel F; Jarufe N; Arrese M; Lammert F; Miquel JF
Liver Int; 2008 Aug; 28(7):935-47. PubMed ID: 18783541
[TBL] [Abstract][Full Text] [Related]
10. Farnesoid X receptor agonism -- a new approach to the treatment of cholesterol gallstone disease.
Doggrell SA
Expert Opin Investig Drugs; 2005 Apr; 14(4):535-8. PubMed ID: 15882126
[TBL] [Abstract][Full Text] [Related]
11. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia.
Evans MJ; Mahaney PE; Borges-Marcucci L; Lai K; Wang S; Krueger JA; Gardell SJ; Huard C; Martinez R; Vlasuk GP; Harnish DC
Am J Physiol Gastrointest Liver Physiol; 2009 Mar; 296(3):G543-52. PubMed ID: 19136377
[TBL] [Abstract][Full Text] [Related]
12. Role of bile acids and bile acid receptors in metabolic regulation.
Lefebvre P; Cariou B; Lien F; Kuipers F; Staels B
Physiol Rev; 2009 Jan; 89(1):147-91. PubMed ID: 19126757
[TBL] [Abstract][Full Text] [Related]
13. FXR, a multipurpose nuclear receptor.
Lee FY; Lee H; Hubbert ML; Edwards PA; Zhang Y
Trends Biochem Sci; 2006 Oct; 31(10):572-80. PubMed ID: 16908160
[TBL] [Abstract][Full Text] [Related]
14. Hypocholesterolemic effects of fatty acid bile acid conjugates (FABACs) in mice.
Leikin-Frenkel A; Parini P; Konikoff FM; Benthin L; Leikin-Gobbi D; Goldiner I; Einarsson C; Gilat T
Arch Biochem Biophys; 2008 Mar; 471(1):63-71. PubMed ID: 18167305
[TBL] [Abstract][Full Text] [Related]
15. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy.
Jiang T; Wang XX; Scherzer P; Wilson P; Tallman J; Takahashi H; Li J; Iwahashi M; Sutherland E; Arend L; Levi M
Diabetes; 2007 Oct; 56(10):2485-93. PubMed ID: 17660268
[TBL] [Abstract][Full Text] [Related]
16. [Innovations in the medical treatment of gallstones and fatty liver: FABACs (Fatty Acid Bile Acid Conjugates)].
Keizman D; Goldiner I; Leikin-Frenkel A; Konikoff FM
Harefuah; 2008 Apr; 147(4):344-9, 373, 372. PubMed ID: 18686819
[TBL] [Abstract][Full Text] [Related]
17. The expanding role of the bile acid receptor FXR in the small intestine.
Cariou B; Staels B
J Hepatol; 2006 Jun; 44(6):1213-5. PubMed ID: 16618512
[No Abstract] [Full Text] [Related]
18. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.
Pellicciari R; Costantino G; Camaioni E; Sadeghpour BM; Entrena A; Willson TM; Fiorucci S; Clerici C; Gioiello A
J Med Chem; 2004 Aug; 47(18):4559-69. PubMed ID: 15317466
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibition protects against diet-induced gallstone formation through modulation of cholesterol and bile acid homeostasis.
Lee EJ; Kim MH; Kim YR; Park JW; Park WJ
Int J Mol Med; 2018 Mar; 41(3):1715-1723. PubMed ID: 29286073
[TBL] [Abstract][Full Text] [Related]
20. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor.
Yang F; Huang X; Yi T; Yen Y; Moore DD; Huang W
Cancer Res; 2007 Feb; 67(3):863-7. PubMed ID: 17283114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
